University of Minnesota Medical School

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Friday, November 3, 2023
University of Minnesota Medical School, EGFR, Key finding attacks, Heart Protection Study, Kidney failure, Kidney, University Center, SGLT2, Kidney disease, Society, American Society of Nephrology, Quality of life, Disease, Division, Clinical trial, ASN, Jay Traver, Abstract, The New England Journal of Medicine, Overload, University, Immunoglobulin A, Focal segmental glomerulosclerosis, Therapy, Patient, Death, International Pediatric Nephrology Association, SAN, Proteinuria, Pharmaceutical industry, Dietary supplement, Medical device, IgA nephropathy, Irbesartan, PROTECT, Nephrology, FSGS, Lancet

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced additional data from two pivotal clinical studies demonstrating sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT) and The New England Journal of Medicine (DUPLEX).

Key Points: 
  • Data from the Phase 3 PROTECT and DUPLEX Studies were presented as late-breaking oral presentations at the American Society of Nephrology (ASN) Kidney Week 2023 and simultaneously published in The Lancet (PROTECT ) and The New England Journal of Medicine (DUPLEX) .
  • The absolute overall change in kidney function from baseline to the end of the study for patients treated with FILSPARI was -5.8 mL/min/1.73m2 compared to -9.5 mL/min/1.73m2 with irbesartan.
  • Treatment with FILSPARI demonstrated lower rates of the composite endpoint of 40% decline in eGFR, kidney failure or death compared to irbesartan.
  • Sparsentan showed a consistent and sustained achievement of complete remission of proteinuria in 18.5% of patients on sparsentan vs. 7.5% for irbesartan.

Nuwellis Announces Board of Directors Transition

Retrieved on: 
Wednesday, November 1, 2023
Capital market, AARP, Johns Hopkins School of Medicine, RBC Capital Markets, St. Olaf College, Business development, News, Hypervolemia, UnitedHealth Group, Internal medicine, Judgement, Gallup, University of Minnesota Medical School, Seniority (financial), Senior, Growth, Caregiver, Delcath Systems, Carlson School of Management, American Express, Head, University, World Bank, Lake Street, CNN, Patient, Hospital, Mayo Clinic, Nursing, MD, Economics, Medicine

“With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board.

Key Points: 
  • “With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board.
  • Dave’s significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives.
  • In turn, our board will benefit from perspectives gained from Archelle’s healthcare policy, clinical, and patient education experience in bringing medical decisions closer to patients and caregivers,” said Nestor Jaramillo Jr, President and CEO of Nuwellis.
  • In addition, Nuwellis announced that Jon Salveson is stepping down from the Board after 10 years of outstanding service.

ChromaCode To Show New Data In Oncology and Blood Based Monitoring at the Association for Molecular Pathology 2023 Annual Meeting and Expo

Retrieved on: 
Tuesday, October 31, 2023
Laboratory, Data analysis, NSCLC, Pathology, MPH, Medical laboratory, AMP, Nested polymerase chain reaction, University of Minnesota Medical School, MD, Corporation, Professor, Translational research, Turnaround time, Software, Development, Fellow, Genomics, Salt Palace, MRD, Blood, University, TAT, Cancer, Diagnosis, Management, Medical imaging

CARLSBAD, Calif., Oct. 31, 2023 /PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable solutions for laboratories, will present new data during a Corporate workshop and present two accepted scientific abstracts at the Association for Molecular Pathology (AMP) 2023 annual meeting, being held at the Salt Palace Convention Center in Salt Lake City, Utah, from November 14-18, 2023.

Key Points: 
  • "The ChromaCode team is proud to participate in this year's preeminent conference for molecular diagnostics, AMP 2023.
  • At the Corporate Workshop, we will be revealing new data showcasing the potential of HDPCR enabled multiplexing and ChromaCode software in transplant and minimal residual disease.
  • We look forward to engaging with fellow attendees at these presentations and at our Booth (1700)" stated Mark McDonough, Chief Executive Officer at ChromaCode.
  • Attendees can expect insights into the latest software tools, data analysis techniques, and their potential to enhance precision and accuracy in molecular testing.

HealthPartners names Ginger Kakacek, MD, chief health plan medical officer

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Health, Hospitals, Practice Management, Insurance, Health Insurance, General Health, MD, Multimedia, Population health, University of Minnesota Medical School, HealthPartners, Methodist Hospital, University, Patient, American Academy, Nursing

HealthPartners today announced that Ginger Kakacek, MD, has been named chief medical officer of its health plan.

Key Points: 
  • HealthPartners today announced that Ginger Kakacek, MD, has been named chief medical officer of its health plan.
  • In this role, she’ll provide leadership and medical oversight of the health plan to ensure members and patients receive high-quality, evidence-based and cost-effective care and services.
  • View the full release here: https://www.businesswire.com/news/home/20231012312786/en/
    Ginger Kakacek, MD, has been named chief medical officer of HealthPartners health plan.
  • She joined the health plan medical director team in 2014 and most recently served as vice president and senior medical director of health and care engagement.

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th

Retrieved on: 
Wednesday, September 6, 2023
Medical genetics, FRCP, University, Royal Free Hospital, University of the Witwatersrand, BioMarin Pharmaceutical, Consultant, Keck School of Medicine of USC, Achondroplasia, Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, National Health Laboratory Service, Charlotte Maxeke Johannesburg Academic Hospital, University of Southern California, BMRN, Division, University of Minnesota Medical School, SAN, NHS foundation trust, Evelina London Children's Hospital, Hospital, Haemophilia, Master of Medicine, Hemostasis, Broadcasting, Instrumentation, Pediatrics, Bachelor of Medicine, Bachelor of Surgery, Endocrinology

SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.

Key Points: 
  • R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th
    SAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m.
  • ET on Tuesday, September 12, 2023.
  • BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.
  • An archived version of the remarks will also be available through the Company's website for a limited time following the event.

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Retrieved on: 
Tuesday, August 22, 2023
Infectious Diseases Society of America, University, Survival, Infection, Toxicity, LNC, IDSA, Trial of the century, Cryptococcosis, Patient, University of Minnesota Medical School, Fungal infection, MPH, Enactment, NYSE, Pharmaceutical industry, MD

While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.

Key Points: 
  • While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.
  • In this randomized trial of 141 HIV-positive individuals afflicted by life-threatening cryptococcal meningitis, the oral amphotericin MAT2203 product combined with oral flucytosine appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than intravenous amphotericin B.
  • The publication of the EnACT data in Clinical Infectious Diseases is yet another milestone for our development program.
  • We would like to thank all the EnACT participants, our dedicated investigators, and the entire clinical study team in Uganda for their commitment to this important clinical trial.”

Annals of Family Medicine: Papers illustrate ways in which federal and insurance policies may negatively influence primary care practice

Retrieved on: 
Tuesday, July 25, 2023
Vaccine, Workforce, Insurance, Annals of Family Medicine, Society, University, Public Service Loan Forgiveness, College, Private, Vaccination, ANN, NHSC, Physician, American Academy, North American Primary Care Research Group, Research, Multimedia, Family medicine, American Board of Family Medicine, Federally Qualified Health Center, American Board of Commissioners for Foreign Missions, Indian Health Service, Acquisition, Patient, University of Minnesota Medical School, Practitioner, College of Family Physicians of Canada, HPV, American Academy of Family Physicians, Health care, National Health Service Corps, American Association for Pediatric Ophthalmology and Strabismus, Forgiveness, Teacher, Pediatrics, Private sector, Nursing, Pharmaceutical industry, Doctor of Philosophy, Annals, PSLF

ANN ARBOR, Mich., July 25, 2023 /PRNewswire/ -- Two papers published in the July/August issue of Annals of Family Medicine address federal policy impact on Family Medicine practice.

Key Points: 
  • ANN ARBOR, Mich., July 25, 2023 /PRNewswire/ -- Two papers published in the July/August issue of Annals of Family Medicine address federal policy impact on Family Medicine practice.
  • The first documents differences in how federal medical school loan repayment programs support doctors who want to practice in rural and underserved areas.
  • The second describes the impact of differences in insurance reimbursement rates for identical care based on specialty and the implications of these differences on patient access to care.
  • Complete editorial content and interactive discussion groups for each published article can be accessed free of charge on the journal's website, www.AnnFamMed.org .

Lustgarten Foundation Announces the Appointment of Two New Board Members

Retrieved on: 
Thursday, July 13, 2023
Linda, Cloud, Pancreatic cancer, Society, Lustgarten Foundation for Pancreatic Cancer Research, Birmingham School of Law, University, American Surgical Association, Senior, Stanford University, PwC, Weak artificial intelligence, IBM/Google Cloud Computing University Initiative, Cancer, Dean, ...And You Will Know Us by the Trail of Dead, Research, Johns Hopkins School of Medicine, Doctor of Philosophy, UAB, Extrapyramidal system, National academy, Computation, National Academy of Medicine, Stanford University School of Medicine, Trustee, University of Minnesota Medical School, Memorial Sloan Kettering Cancer Center, MSK, FACS, Artificial intelligence, AI, Breast cancer, Pharmaceutical industry, Medical device, MD, Medicine

WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS. Dr. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. Dr. Penberthy is a visionary engineering leader with extensive expertise in artificial intelligence (AI) and technology, specifically in the healthcare space.

Key Points: 
  • Selwyn M. Vickers, MD, FACS, and Scott Penberthy, PhD, MS, join the Lustgarten Foundation Board of Directors.
  • WOODBURY, N.Y., July 13, 2023 /PRNewswire-PRWeb/ -- The Lustgarten Foundation, the nation's largest private funder of pancreatic cancer research, today announced the appointment of two new board members: Selwyn M. Vickers, MD, FACS , and Scott Penberthy, PhD, MS .
  • "We are honored to welcome Dr. Vickers and Dr. Penberthy to the Lustgarten Foundation Board of Directors," said Linda Tantawi, CEO of the Lustgarten Foundation.
  • "At the Foundation, we firmly believe in the fundamental role of innovative and cutting-edge research in solving the complexities of pancreatic cancer.

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023
University, Parsemus Foundation, COVID-19, Ivermectin, Research, Multimedia, COVID, The Lancet, Preprint, MD, Metformin, Patient, University of Minnesota Medical School, Randomized controlled trial, Viral load, Health, Death, Pfizer, Disease, Pharmaceutical industry, Long COVID

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023
University, Parsemus Foundation, COVID-19, Ivermectin, Research, COVID, The Lancet, Preprint, MD, Metformin, Patient, University of Minnesota Medical School, Randomized controlled trial, Viral load, Health, Death, Pfizer, Disease, Pharmaceutical industry, Long COVID

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.